Can Targeting Glutamine Metabolism be a Therapeutic Strategy?
Given the dependency of many cancer cells on glutamine, targeting glutamine metabolism has emerged as a promising therapeutic strategy. Inhibitors of glutaminase, such as CB-839, are currently being investigated in clinical trials. These inhibitors aim to starve cancer cells of glutamine, thereby impeding their growth and survival. However, challenges remain, including the development of resistance and the potential impact on normal cells that also utilize glutamine.